FDA won’t let Henry Ford use hydroxychloroquine for COVID-19 patients

Maia Anderson –
Thursday, August 13th, 2020
Print|Email.

Henry Ford formerly published a questionable study that recommended the drug, typically used as an anti-malarial medication and for individuals with autoimmune diseases, cut the COVID-19 death rate in half. The research study contradicted others that revealed the drug didnt assist COVID-19 patients and had severe adverse effects.

” The U.S. Food and Drug Administration informed us that it would not approve our ask for an emergency situation use authorization for hydroxychloroquine for a segment of COVID-19 clients meeting really particular requirements,” Adnan Munkarah, MD, Henry Fords executive vice president and chief scientific officer, told the Detroit Free Press..

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by click on this link.

After the FDA withdrawed emergency permission for hydroxychloroquine to deal with COVID-19, Henry Ford Health System in Detroit filed for permission to keep using it. The agency rejected the demand today, the Detroit Free Press reported..

More articles on pharmacy: Kamala Harris stance on Big Pharma: 5 things to knowLouisiana pharmacy CEO pleads guilty to $50M reimbursement fraudSpecialty drug price caps drastically reduce out-of-pocket expenses without increasing health strategy spending.

The health system said it still prepares to continue a study of hydroxychloroquine called the WHIP COVID-19 research study, which is the first massive U.S. study to investigate whether hydroxychloroquine can prevent COVID-19 in 3,000 health care workers and very first responders..